ArticleJournal of photochemistry and photobiology. B, Biology2021
Potentiated antimicrobial blue light killing of methicillin resistant Staphylococcus aureus by pyocyanin.
Article in Journal of photochemistry and photobiology. B, Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Inhibitory Efficacy of Medicinal Plant Extracts from the Family Acanthaceae Against Skin Pathogenic Bacteria, Antioxidant and Anti-Inflammatory Activities.Plants (Basel, Switzerland) · 2026Article
- Amoebicidal effect of pyocyanin and its mechanism of action againstCurrent research in parasitology & vector-borne diseases · 2026Article
- A Collection and Analysis of Simplified Data for a Better Understanding of the Complex Process of Biofilm Inactivation by Ultraviolet and Visible Irradiation.Microorganisms · 2025Review
- An insight into pyocyanin: production, characterization, and evaluation of its in vitro antibacterial, antifungal, antibiofilm and in vivo anti-schistosomal potency.BMC microbiology · 2025Article
- Efficient Photolysis of Multidrug-Resistant Polymicrobial Biofilms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exposure to blue light reduces antimicrobial resistantFrontiers in microbiology · 2024Article
- New Weapons to Fight againstAntibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial Resistance: Is There a 'Light' at the End of the Tunnel?Antibiotics (Basel, Switzerland) · 2023Review
- An Approach to Improve Energy Efficiency during Antimicrobial Blue Light Inactivation: Application of Pulse-Width Modulation Dimming to Balance Irradiance and Irradiation Time.Antibiotics (Basel, Switzerland) · 2023Article
- Managing Corneal Infections: Out with the old, in with the new?Antibiotics (Basel, Switzerland) · 2023Review
- Safer school with near-UV technology: novel applications for environmental hygiene.Journal of environmental health science & engineering · 2023Article
- The two faces of pyocyanin - why and how to steer its production?World journal of microbiology & biotechnology · 2023Review
- An antimicrobial blue light device to manage infection at the skin-implant interface of percutaneous osseointegrated implants.PloS one · 2023Article
- Antimicrobial Blue Light for Prevention and Treatment of Highly InvasiveFrontiers in microbiology · 2022Article
- Antimicrobial blue light: A 'Magic Bullet' for the 21st century and beyond?Advanced drug delivery reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
As antimicrobial resistance continues to threaten the efficacy of conventional antibiotic therapy, it is paramount that we investigate innovative approaches to treat infectious diseases. In this study, we investigated the antimicrobial capabilities of the innovative combination of antimicrobial blue light (aBL; 405 nm wavelength) with the Pseudomonas aeruginosa pigment pyocyanin against methicillin resistant Staphylococcus aureus (MSRA. We explored the effects of different radiant exposures of aBL and increasing concentrations of pyocyanin against planktonic cells and those within biofilms. In addition, we investigated the effect of the aBL/pyocyanin on the endogenous staphyloxanthin pigment, as well as the role of hydrogen peroxide and singlet oxygen scavenging in the efficacy of this combination. Lastly, we investigated the potential for the aBL/pyocyanin to reduce the MRSA burden within a proof-of-principle mouse abrasion infection model. We found pyocyanin to be a powerful potentiator of aBL activity under all in vitro conditions tested. In addition, we serendipitously discovered the capability of the aBL/pyocyanin combination to bleach staphyloxanthin within colonies of MRSA. Furthermore, we established that singlet oxygen is an important mediator during combined aBL/pyocyanin exposure. Moreover, we found that the combination of aBL and pyocyanin could significantly reduce the viability of MRSA within a proof-of-principle early onset MRSA skin abrasion infection. Exposure to the treatment did not have deleterious effects on skin tissue. In conclusion, the combination of aBL and pyocyanin represents a potentially powerful therapeutic modality for the treatment of infections caused by MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.